PLYX
Polaryx Therapeutics, Inc.
$2.81
+0.23 (+8.91%)
At close · Jul 2
Market Cap
$133.03M
Shares
47,343,297
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.81
Open$2.65
Day$2.58–2.91
52W$2.07–48.91
Avg vol 30d248K
Short int442K · 0.9% float · 2.1d
Short vol27%
DataFeb 2026–Jul 2026
Filing10-Q · May 15
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Sell
◦
50 / 200-day cross
no cross
−
Price vs 50-day avg
−14% below
◦
RSI (14)
51 · neutral
+
MACD trend
positive
−
52-week position
2% · near low
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50/200-day averages unavailable
+
Institutional flow
+14 funds added
+
Insider flow
Net +$360.0K over 90 days · 0% sells
−
Short interest
0.93% of float · ▲ +27.2% MoM · 2.1 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
14 holders — 13F breadth
Fundamentals
Excellent
+
EPS growth
+78% Y/Y
+
Balance sheet
net cash $5.1M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
no cross
Neutral
Price vs 50-day avg
−14% below
Bearish
RSI (14)
51 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
2% · near low
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+14 funds added
Insider flow
Accumulating
Net +$360.0K over 90 days · 0% sells
Short interest
Rising
0.93% of float · ▲ +27.2% MoM · 2.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
14 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $2
Now $3 · 2%
52-wk high $49
vs 50-day avg -14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PLYX
this stock
Polaryx Therapeutics, Inc.
|
$133.03M | — | — | — | 0.9% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PLYX | +21.7% | +11.5% | — | +5.6% | — |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +20.2% | +12.8% | — | +5.9% | — |